Matinas BioPharma
MTNB
48 hedge funds and large institutions have $6.15M invested in Matinas BioPharma in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
463% more capital inflows, than outflows
Capital inflows: $2.78M | Capital outflows: $493K
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
14% more funds holding
Funds holding: 42 → 48 (+6)
3.79% more ownership
Funds ownership: 11.71% → 15.5% (+3.8%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Highbridge Capital Management
New York
|
+$1.93M |
| 2 |
Alliance Wealth Management Group
Flemington,
New Jersey
|
+$342K |
| 3 |
Towercrest Capital Management
Newtown,
Pennsylvania
|
+$342K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$45K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arkadios Wealth Advisors
Atlanta,
Georgia
|
-$440K |
| 2 |
Sargent Investment Group
Bethesda,
Maryland
|
-$21.5K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$14.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.2K |
| 5 |
Trajan Wealth
Scottsdale,
Arizona
|
-$1.63K |
MTNB Hedge Fund Activity: Q2 2024 in Review
48 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2024, worth a combined $6.15M — down 11% from $6.91M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MTNB positions and 3 closed out — a net gain of 6 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $1.93M. The largest seller was Arkadios Wealth Advisors, exiting entirely with an estimated $440K sold.
- 48 institutional investors held Matinas BioPharma (MTNB) as of Q2 2024, up from 42 in Q1 2024.
- Funds reported $6.15M of Matinas BioPharma stock for Q2 2024, down 11% quarter-over-quarter.
- 9 funds opened new Matinas BioPharma positions in Q2 2024 and 3 closed out, a net change of +6 holders.
- The largest Matinas BioPharma buyer in Q2 2024 was Highbridge Capital Management, an estimated $1.93M added.
- The largest Matinas BioPharma seller in Q2 2024 was Arkadios Wealth Advisors, an estimated $440K sold.
Based on aggregated 13F filings for Q2 2024.